Bellini duct carcinoma
DOI:
https://doi.org/10.4322/acr.2020.230Keywords:
Kidney Neoplasms, Carcinoma, Renal Cell, Kidney Tubules, CollectingAbstract
The modern era has brought an appreciation that renal cell carcinoma (RCC) includes diverse subtypes derived from the various parts of the nephron, each with its distinctive genetic basis and tumor biology. Carcinoma of the collecting ducts of Bellini (CDC) is a rare subtype of RCC, with a predictably poor prognosis. This rare subtype represents less than 1% of all kidney carcinomas. It derives from presumably numerous chromosomal losses. It is of chief importance to differentiate CDC from other types of renal cell cancer. Typically, it is characterized by a firm, centrally located tumor with infiltrative borders. Regarding the histopathologic characteristics, we can find complex, highly infiltrative cords with inflamed (desmoplastic) stroma, with high-grade nuclei and mitoses. Most reported cases of CDC had been high grade, advanced stage, and unresponsive to conventional therapies. This rare form of disease highlights the importance of multidisciplinary teams in the management of cancer patients.
Downloads
References
Turajlic S, Swanton C, Boshoff C. Kidney cancer: the next decade. J Exp Med. 2018;215(10):2477-9. http://dx.doi.org/10.1084/jem.20181617. PMid:30217855.
Fleming S, Lewi HJ. Collecting duct carcinoma of the kidney. Histopathology. 1986;10(11):1131-41. http://dx.doi.org/10.1111/j.1365-2559.1986.tb02553.x. PMid:3542784.
Tokuda N, Naito S, Matsuzaki O, Nagashima Y, Ozono S, Igarashi T. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol. 2006;176(1):40-3. http://dx.doi.org/10.1016/S0022-5347(06)00502-7. PMid:16753362.
Mishra AK, Manikandan R, Dorairajan LN, Mittal JK, Rekha JS. Bellini duct carcinoma: a rare entity. J Clin Diagn Res. 2016;10(10):PD01-02. http://dx.doi.org/10.7860/JCDR/2016/21335.8613. PMid:27891395.
Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20(9):2376-81. http://dx.doi.org/10.1200/JCO.2002.11.123. PMid:11981011.
Dason S, Allard C, Sheridan-Jonah A, et al. Management of renal collecting duct carcinoma: a systematic review and the McMaster experience. Curr Oncol. 2013;20(3):e223-32. http://dx.doi.org/10.3747/co.20.1230. PMid:23737692.
Ahrens M, Scheich S, Hartmann A, Bergmann L. Non-clear cell renal cell carcinoma: pathology and treatment options. Oncol Res Treat. 2019;42(3):128-35. http://dx.doi.org/10.1159/000495366. PMid:30799404.
Albadine R, Schultz L, Illei P, et al. PAX8 (+)/p63 (-) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract. Am J Surg Pathol. 2010;34(7):965-9. http://dx.doi.org/10.1097/PAS.0b013e3181dc5e8a. PMid:20463571.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Autopsy and Case Reports

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright
Authors of articles published by Autopsy and Case Report retain the copyright of their work without restrictions, licensing it under the Creative Commons Attribution License - CC-BY, which allows articles to be re-used and re-distributed without restriction, as long as the original work is correctly cited.